You Lu

List of Publications by Year in Descending Order

Source: https://exaly.com/author-pdf/9579815/you-lu-publications-by-year.pdf

Version: 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

4	233	2	5
papers	citations	h-index	g-index
5	297	4.3	1.64
ext. papers	ext. citations	avg, IF	L-index

#	Paper	IF	Citations
4	A phase I study of the tyrosine kinase inhibitor anlotinib combined with platinum/pemetrexed-based chemotherapy in untreated nonsquamous non-small-cell lung cancer. <i>Investigational New Drugs</i> , 2021 , 1	4.3	0
3	A phase I dose-reduction study of apatinib combined with pemetrexed and carboplatin in untreated EGFR and ALK negative stage IV non-squamous NSCLC. <i>Investigational New Drugs</i> , 2020 , 38, 478-484	4.3	1
2	Synergy between peroxisome proliferator-activated receptor lagonist and radiotherapy in cancer. <i>Cancer Science</i> , 2018 , 109, 2243-2255	6.9	8
1	BEYOND: A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Phase III Study of First-Line Carboplatin/Paclitaxel Plus Bevacizumab or Placebo in Chinese Patients With Advanced or Recurrent Nonsquamous Non-Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2015 , 33, 2197-2	2.2 04	224